ABSTRACT
Abstract Encapsulating Peritoneal Sclerosis (EPS) is a severe and rare condition frequently associated with peritoneal dialysis, characterized by bowel obstruction, with lethal consequences in 20% of the patients. The disease presents as a mass of fibrous tissue encapsulating visceral organs that may potentially compromise digestive tract function. This report describes the case of a patient under peritoneal dialysis (PD) due to chronic kidney disease secondary to focal segmental glomerulosclerosis diagnosed with EPS. The patient had undergone two living-donor kidney transplant procedures. Surgical techniques and clinical measures employed to unravel bowel obstruction are described, which have been shown to ameliorate EPS secondary complications. Parenteral nutrition has significantly contributed to afford adequate nutrition, improving tissue healing as well as serum protein levels, vitamins and electrolytes. Therapy with tamoxifen and sodium thiosulfate effectively delayed the development of EPS.
Resumo A peritonite esclerosante encapsulante (PEE) é uma condição rara e grave, frequentemente associada à diálise peritoneal, caracterizada por obstrução intestinal, que pode ter uma evolução fatal em 20% dos pacientes. Apresenta-se como uma massa de tecido fibroso, recobrindo os tecidos viscerais, e pode comprometer o funcionamento fisiológico de todo o aparelho digestivo. O presente estudo relata um caso de PEE decorrente de diálise peritoneal (DP) devido à insuficiência renal por glomeruloesclerose focal e segmentar. No caso relatado, a paciente foi submetida a DP e passou por dois transplantes renais intervivos. São descritas as técnicas cirúrgicas e as medidas clínicas adotadas, que se revelaram úteis na resolução da obstrução intestinal, com melhora dos efeitos secundários da PEE. A dieta parenteral mostrou ser um importante fator para a manutenção do aporte nutricional, auxiliando na cicatrização e no nível sérico de proteínas, vitaminas e eletrólitos. A terapia com tamoxifeno e a administração de hipossulfito de sódio foram eficientes para retardar o avanço da PEE.
Subject(s)
Humans , Female , Child, Preschool , Adult , Peritonitis , Kidney Transplantation , Peritoneal Dialysis , Peritoneal Fibrosis , Immunosuppressive AgentsABSTRACT
La esclerosis peritoneal encapsulante es una complicación poco común, pero muy grave, de la diálisis peritoneal. Esta complicación está asociada con altas tasas de morbilidad y mortalidad. El diagnóstico clínico requiere la presencia de obstrucción intestinal o función gastrointestinal alterada con signos patológicos y radiológicos de encapsulamiento intestinal. El diagnóstico patognomónico es solo con la realización de una biopsia peritoneal. El mecanismo patogénico exacto de esta entidad sigue siendo desconocido, aunque se asocia firmemente con el tiempo de duración del paciente en el tratamiento con diálisis peritoneal. Se presenta un caso clínico de esclerosis peritoneal encapsulante y se analizan las manifestaciones clínicas, diagnóstico, tratamiento, pronóstico y prevención(AU)
Encapsulating peritoneal sclerosis is a rare but very serious complication of peritoneal dialysis. This complication is associated with high morbidity and mortality rates. Clinical diagnosis is based on the presence of intestinal obstruction or altered gastrointestinal function with pathological and radiological signs of intestinal encapsulation. The pathognomonic diagnosis is achieved only by performing peritoneal biopsy. The exact pathogenic mechanism of this entity remains unknown, although it is strongly associated with the duration of the patient with peritoneal dialysis. We report a clinical case of encapsulating peritoneal sclerosis and the clinical manifestations, diagnosis, treatment, prognosis and prevention are analyzed(AU)
Subject(s)
Humans , Male , Adult , Peritoneal Dialysis/adverse effects , Renal Insufficiency, Chronic/diagnosis , Peritoneal Fibrosis/complications , Peritoneal Fibrosis/pathologyABSTRACT
Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of peritoneal dialysis. A total of 50% of the patients died within 12 months after being diagnosed. There are no obvious clinical symptoms in the early stage of EPS, which is easy to be missed. And there are few case reports of EPS in early stage. On December 22, 2018, a 70-year-old male patient undergoing peritoneal dialysis for 17 months, who was diagnosed as EPS, was admitted to the Department of Nephrology, the Third Xiangya Hospital, Central South University. The patient's peritoneal dialysis catheter was obstructed after peritonitis. The peritoneal dialysis fluid couldn't be drain in and out of the abdominal cavity. Therefore, the laparoscopy was performed to repair the catheter. The operation in progress showed that the peritoneum was slightly thickened and the ileocecal intestinal tube was closely adhered to the parietal peritoneum where the catheter was wrapped, indicating the early stage of EPS. Peritoneal relaxation was performed. The patient's catheter was normal after adhesiolysis. He underwent hemodialysis, nutritional supporting as well as peritoneal dialysis transition, etc. The peritonitis was controlled after 10 days and the peritoneal dialysis was resumed. After discharge from hospital, the patient took moxifloxacin for 2 more weeks. We followed up the patient for 6 months. The automated peritoneal dialysis is maintained, and everything remains normal. Clinicians need to improve understanding of EPS. Early diagnosis and laparoscopic adhesiolysis is helpful to continue peritoneal dialysis treatment.
Subject(s)
Aged , Humans , Male , Early Diagnosis , Peritoneal Dialysis/adverse effects , Peritoneal Fibrosis/pathology , Peritoneum , Peritonitis/pathology , Sclerosis/pathologyABSTRACT
BACKGROUND@#Peritoneal fibrosis is the primary reason that patients with end-stage renal disease (ESRD) have to cease peritoneal dialysis. Peritonitis caused by Gram-negative bacteria such as Escherichia coli (E. coli) were on the rise. We had previously shown that matrine inhibited the formation of biofilm by E. coli. However, the role of matrine on the epithelial-mesenchymal transition (EMT) in peritoneal mesothelial cells under chronic inflammatory conditions is still unknown.@*METHODS@#We cultured human peritoneal mesothelial cells (HPMCs) with lipopolysaccharide (LPS) to induce an environment that mimicked peritonitis and investigated whether matrine could inhibit LPS-induced EMT in these cells. In addition, we investigated the change in expression levels of the miR-29b and miR-129-5p.@*RESULTS@#We found that 10 μg/ml of LPS induced EMT in HPMCs. Matrine inhibited LPS-induced EMT in HPMCs in a dose-dependent manner. We observed that treatment with matrine increased the expression of E-cadherin (F = 50.993, P < 0.01), and decreased the expression of alpha-smooth muscle actin (F = 32.913, P < 0.01). Furthermore, we found that LPS reduced the expression levels of miR-29b and miR-129-5P in HPMCs, while matrine promoted the expression levels of miR-29b and miR-129-5P.@*CONCLUSIONS@#Matrine could inhibit LPS-induced EMT in HPMCs and reverse LPS inhibited expressions of miR-29 b and miR-129-5P in HPMCs, ultimately reduce peritoneal fibrosis. These findings provide a potential theoretical basis for using matrine in the prevention and treatment of peritoneal fibrosis.
Subject(s)
Humans , Actins , Metabolism , Alkaloids , Therapeutic Uses , Cadherins , Metabolism , Cells, Cultured , Epithelial-Mesenchymal Transition , Epithelium , Fibrosis , Genetics , Metabolism , Lipopolysaccharides , Toxicity , MicroRNAs , Metabolism , Peritoneal Fibrosis , Drug Therapy , Quinolizines , Therapeutic UsesABSTRACT
BACKGROUND: We investigated the effects of tranilast on epithelial-to-mesenchymal transition (EMT) in an animal model and on the EMT signaling pathway in human peritoneal mesothelial cells (HPMCs).METHODS: We performed in vitro studies (cytotoxicity, cell morphology, and western blot analyses) on HPMCs from human omenta, along with in vivo studies (peritoneal membrane function and morphometric and immunohistochemical analyses) on Sprague Dawley rats. Thirty-two rats were divided into three groups: control (C) group (peritoneal dialysis [PD] catheter but not infused with dialysate), PD group (4.25% glucose-containing dialysate), and PD + tranilast group (4.25% glucose-containing dialysate along with tranilast).RESULTS: In in vitro experiments, transforming growth factor-beta 1 (TGF-β1) increased α-smooth muscle actin and Snail expression and reduced E-cadherin expression in HPMCs. TGF-β1 also reduced cell contact, induced a fibroblastoid morphology, and increased phosphorylation of Akt, Smad2, and Smad3 in HPMCs. Tranilast significantly inhibited TGF-β1-induced EMT and attenuated these morphological changes in HPMCs. In in vivo studies, after 6 weeks of experimental PD, the peritoneal membrane was significantly thicker in the PD group than in the C group. Tranilast protected against PD-induced glucose mass transfer change and histopathological changes in rats.CONCLUSION: Tranilast prevented EMT both in HPMCs triggered with TGF-β1 and in rats with PD-induced peritoneal fibrosis. Thus, tranilast may be considered a therapeutic intervention that enables long-term PD by regulating TGF-β1 signaling pathways.
Subject(s)
Animals , Humans , Rats , Actins , Blotting, Western , Cadherins , Catheters , Dialysis , Epithelial-Mesenchymal Transition , Fibrosis , Glucose , In Vitro Techniques , Membranes , Models, Animal , Peritoneal Dialysis , Peritoneal Fibrosis , Peritoneum , Phosphorylation , Rats, Sprague-Dawley , SnailsABSTRACT
BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a rare but near-fatal complication of peritoneal dialysis (PD). Despite the high mortality rate of EPS, the surgical treatment strategy of severe EPS is yet to be established.METHODS: We retrospectively analyzed outcomes of patients with EPS who underwent enterolysis for intractable EPS at Seoul National University Hospital between 2001 and 2018. EPS was diagnosed based on the clinical symptoms and radiological findings of abdominal computed tomography (CT). CT scans were scored according to an EPS scoring system that assessed peritoneal thickening and calcification as well as bowel thickening, tethering, loculation, and dilatation.RESULTS: Thirteen patients (nine males and four females; age, 48 [29–63] years) underwent enterolysis for severe EPS. PD duration (11 [6–21] years) was not associated with survival. Two patients were newly diagnosed with EPS following kidney transplantation. Five patients died of infectious complications immediately after the surgery. Eight patients survived after the first surgery; however, five of them underwent reoperation but died of persistent infection, fistula formation, or adhesive bowel obstruction. Four young (< 60 years) male patients with relatively low CT scan scores (< 13) survived for > 2 years after the first surgery. Median survival duration from EPS diagnosis was 22 (1.3–184) months and that from the first surgery was 9 (0.3–153) months.CONCLUSION: The high mortality rate of EPS suggests the importance of appropriate surgical intervention in young symptomatic male EPS patients with relatively low CT scan scores.
Subject(s)
Female , Humans , Male , Adhesives , Diagnosis , Dilatation , Fistula , Kidney Transplantation , Korea , Mortality , Peritoneal Dialysis , Peritoneal Fibrosis , Reoperation , Retrospective Studies , Seoul , Tomography, X-Ray ComputedABSTRACT
Resumen Introducción La peritonitis esclerosante encapsulada es una inflamación crónica del peritoneo caracterizada por la formación progresiva de colágeno que produce un engrosamiento peritoneal que encapsula las asas del intestino delgado, produciendo una obstrucción intestinal. Caso clínico Varón de 83 años portador de catéter de derivación ventriculoperitoneal de baja presión desde hacía 8 años. Acude a Urgencias por clínica de obstrucción intestinal, con hallazgos radiológicos en relación con obstrucción de intestino delgado en probable relación con catéter de derivación ventriculoperitoneal, por lo que se decide realizar intervención quirúrgica urgente. Se confirmó la obstrucción intestinal y un cambio de calibre del íleon terminal. El intestino delgado estaba dilatado formando un ovillo, englobado por una pequeña cápsula fibrosa. Se realizó adhesiólisis y hemicolectomía derecha con resección del segmento intestinal afectado. La anatomía patológica fue compatible con peritonitis esclerosante encapsulada. Conclusiones La peritonitis esclerosante encapsulada es una causa poco frecuente y potencialmente grave de obstrucción intestinal y su forma secundaria está habitualmente asociada a la diálisis peritoneal crónica. Su diagnóstico radiológico es difícil y el tratamiento de elección es quirúrgico. Debemos considerarla en casos de obstrucción intestinal en pacientes portadores de derivación ventriculoperitoneal.
Introduction Sclerosing encapsulating peritonitis is a chronic inflammation of the peritoneum characterized by the progressive accumulation of collagen. This leads to a thickening of the peritoneum, encapsulating loops of small bowel and causing intestinal obstruction. Case report 83 year old male, carrying a ventriculoperitoneal low pressure shunt for 8 years. The patient was admitted for emergency surgery after presentation for possible intestinal obstruction with radiological findings consistent with small bowel obstruction, probably related to the catheter of the ventriculoperitoneal shunt. Surgery confirmed bowel obstruction and a change of gauge of the terminal ileum. The small bowel was dilated into a ball, encased by a small fibrous capsule. Adhesiolysis and right hemicolectomy was performed with resection of the affected bowel segment. The pathology was consistent with sclerosing encapsulating peritonitis. Conclusions Sclerosing encapsulating peritonitis is a rare and potentially serious cause of bowel obstruction and its secondary form is usually associated with chronic peritoneal dialysis. The radiological diagnosis is difficult and the treatment of choice is surgical. We must consider it in cases of intestinal obstruction in patients with ventriculoperitoneal shunt.
Subject(s)
Humans , Male , Aged, 80 and over , Ventriculoperitoneal Shunt/adverse effects , Peritoneal Fibrosis/surgery , Peritoneal Fibrosis/etiology , Intestinal Obstruction/etiology , Peritoneal Fibrosis/diagnostic imaging , Intestinal Obstruction/diagnostic imaging , Intestine, SmallABSTRACT
Abstract Patients with chronic kidney disease (CDK) can develop several diseases caused by the renal replacement therapy. Here we report a rare complication of peritoneal dialysis, the encapsulating peritoneal sclerosis (EPS) in which the peritoneal tissue is gradually replaced by fibrous tissue. The patient in question, after late loss of renal graft and conversion to peritoneal dialysis, evolved with multiple hospitalizations for spontaneous bacterial infections, in recent admission, he was diagnosed with sub-occlusive abdomen secondary to the EPS. Five days after, presented with intestinal obstruction requiring surgical approach by laparotomy, being performed with right colectomy, enterectomy, enteroraphy and ileostomy with drainage. The patient progressed well and follows on prednisone and tamoxifen-associated with intermittent hemodialysis.
Resumo No contexto da insuficiência renal crônica (IRC), os pacientes estão sujeitos a diversas patologias advindas da própria terapêutica de substituição renal. Relatamos aqui uma complicação rara da diálise peritoneal, a peritonite esclerosante encapsulante (PEE), na qual o tecido peritoneal é progressivamente substituído por tecido fibroso. O paciente em questão, após perda tardia de enxerto renal e conversão para terapêutica dialítica peritoneal evoluiu com múltiplas internações por infecções bacterianas espontâneas, em último internamento, foi diagnosticado com abdome sub-oclusivo secundário à PEE. Após 5 dias apresentou quadro de abdome obstrutivo com necessidade de abordagem cirúrgica por laparotomia exploradora, sendo realizado colectomia direita, enterectomia, enterorrafia e ileostomia com drenagem. O paciente evolui bem e segue em tratamento com prednisona e tamoxifeno associado à hemodiálise intermitente.
Subject(s)
Humans , Male , Middle Aged , Peritoneal Dialysis/adverse effects , Peritoneal Fibrosis/etiologyABSTRACT
Um cão SRD, com cinco anos e histórico de ascite de evolução lenta com estruturas palpáveis foi submetido a exames clínicos, os quais foram inconclusivos. A laparotomia exploratória revelou que a cavidade abdominal estava repleta de líquido serossanguinolento e de múltiplos nódulos de diferentes tamanhos, com superfície irregular, aderidos aos peritônios visceral e parietal, sugestivos de neoplasia maligna. A eutanásia, seguida da necropsia para a coleta de amostras para o diagnóstico histopatológico, foi indicada. O exame anatomopatológico revelou nódulos sésseis e resistentes ao corte, constituídos de tecido conjuntivo fibroso e trabéculas ósseas em arranjo de osso esponjoso e osteoclastos em atividade. O diagnóstico definitivo foi peritonite encapsulante esclerosante.(AU)
A 5-year-old dog with chronic ascites was submitted to several clinical exams, which were inconclusive. Laparotomy revealed abdominal serosanguinous fluid and multiple nodules of several sizes with irregular surface, with visceral and parietal adhesion to the peritoneum, resembling malignant neoplasia. Euthanasia followed by necropsy and collection of samples to histopathological diagnosis was performed. Pathological exam revealed sessile nodules resistant to cut and the microscopy evaluation showed fibrous connective tissue and trabecular bone with sponge bone arrangement associated with active osteoclasts. The definitive diagnosis was sclerosing encapsulating peritonitis.(AU)
Subject(s)
Animals , Dogs , Peritoneal Fibrosis/veterinary , Peritonitis/veterinary , Gastrointestinal Hemorrhage/veterinary , Laparotomy/veterinaryABSTRACT
Background: Encapsulating peritoneal sclerosis (EPS) is a complication of peritoneal dialysis (PD) with a low prevalence but high mortality. It is characterized by peritoneal inflammation and fibrosis with subsequent development of intestinal encapsulation. It is associated with a long lapse on PD, frequent episodes of peritonitis, high glucose solution use, and high peritoneal transport status. Aim: To report the clinical features of patients on PD, who developed EPS. Material and Methods: Review of medical records of 12 patients aged 43 ± 10 years (eight women) who developed EPS. Results: The mean time spent on PD was 98 months. The main clinical manifestations were abdominal pain in 82% and ultrafiltration failure in 63%. In 92%, there was a history of peritonitis and 75% had high peritoneal transport at the time of diagnosis. The main findings in computed tomography were peritoneal calcification and thickening. There was a biopsy compatible with the diagnosis in 10 cases. Treatment consisted in withdrawal from PD, removal of PD catheter and the use of corticoids and tamoxifen. After withdrawal from PD 50% of patients became asymptomatic. The rest had intermittent abdominal pain and altered bowel movements. Two patients died (17%). Conclusions: EPS is a serious complication of PD, which should be suspected in any patient with compatible clinical symptoms, long time on PD, multiple episodes of peritonitis and high peritoneal transport profile.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Peritonitis/diagnosis , Peritonitis/etiology , Peritoneal Dialysis/adverse effects , Peritoneal Fibrosis/etiology , Peritonitis/pathology , Peritonitis/therapy , Chile , Retrospective Studies , Risk Factors , Peritoneal Fibrosis/pathology , Peritoneal Fibrosis/therapy , Kidney Failure, ChronicABSTRACT
Encapsulating peritoneal sclerosis (EPS) is a rare cause of intestinal obstruction by a thick fibrous membrane wrapping around the small intestine. It is a possible complication after liver transplantation (LT) that can be fatal. This report describes 2 cases of EPS after LT that were successfully treated with surgery, corticosteroids, tamoxifen, and mammalian target of rapamycin inhibitor. After treatment in both cases, the patients were able to start oral feeding and have been symptom free for more than 1 year. These cases suggests that for the management of EPS, surgical treatment is mandatory when the patients present with symptoms of intestinal obstruction or if there are findings suggestive of decreased mural perfusion. Surgery should be accompanied with medical treatment to prevent the relapse of EPS.
Subject(s)
Humans , Adrenal Cortex Hormones , Intestinal Obstruction , Intestine, Small , Liver Transplantation , Liver , Membranes , Perfusion , Peritoneal Fibrosis , Recurrence , Sirolimus , Tamoxifen , Transplant RecipientsABSTRACT
Abstract INTRODUCTION: We evaluated the associations between interleukin-10 (IL-10) gene polymorphisms -G1082A/-C819T/-C592A and periportal fibrosis regression after specific treatment for schistosomiasis. METHODS: This retrospective cohort study involved 125 Brazilian patients infected with Schistosomiasis mansoni, who were followed up for 2 years after specific treatment to estimate the probability of periportal fibrosis regression. RESULTS: There was no evidence of associations between IL-10 polymorphisms and periportal fibrosis regression after treatment. CONCLUSIONS: There was no evidence of associations between gene promoter polymorphisms of IL-10 and the regression of periportal fibrosis in this Brazilian population.
Subject(s)
Humans , Schistosomiasis mansoni/complications , Interleukin-10/genetics , Peritoneal Fibrosis/genetics , Polymorphism, Genetic , Severity of Illness Index , Retrospective Studies , Peritoneal Fibrosis/parasitology , Peritoneal Fibrosis/drug therapyABSTRACT
Se presenta el caso de un hombre de 69 años inmunosuprimido, con insuficiencia renal en hemodiálisis, con cuadro de dolor abdominal crónico y enfermedad diarreica aguda, que progresó a obstrucción intestinal, por lo que fue llevado a laparoscopia diagnóstica que reportó carcinomatosis peritoneal, pero cuyo diagnóstico histológico final fue tuberculosis peritoneal.
This is a case study of a 69 year old immunosuppressed man with renal failure who was on hemodialysis. He developed chronic abdominal pain and acute diarrhea that progressed to intestinal obstruction. Diagnostic laparoscopy reported peritoneal carcinomatosis, but histological diagnosis showed that it was peritoneal tuberculosis.
Subject(s)
Humans , Male , Aged , Immunosuppression Therapy , Peritoneal Fibrosis , Peritonitis, Tuberculous , Renal Insufficiency, ChronicABSTRACT
Long term peritoneal dialysis (PD) is often associated with peritoneal fibrosis. The aim of this study was to explore the effect of emodin on PD-related peritoneal fibrosis and its related cellular and molecular mechanism. PD-related peritoneal fibrosis rats and cultured rat peritoneal mesothelial cells were recruited in the experiment. PD-related peritoneal fibrosis was induced by intraperitoneal injection of lactate-buffered solution containing 4.25% glucose. The peritoneal equilibrium test (PET) was performed at the end of 2 weeks, 4 weeks, and 6 weeks, respectively. HE staining and Masson staining were used for histopathological evaluation. Enzyme linked immunosorbent assay (ELISA) was used to measure the plasma N-terminal procollagen III propeptide (PIIINP) level. Real-time PCR technique was used to detect the mRNA levels of Notch1, Jagged-1, and Hes-1 in peritoneal tissue. Western blot was applied to identify the protein levels of Notch1, Jagged-1, Hes-1, and Notch intracellular domain (NICD). In vitro, Notch1 overexpressing or knockdown rat peritoneal mesothelial cells were established and Western blot was used to examine the effect of emodin on the expressions of Hes-1 and Hey. Compared with the control group, HE staining revealed that PD rats suffered from decreasing in mesothelial cells, or detaching from surface of parietal peritoneum, accompanied by infiltration of inflammatory cells; Masson staining result showed thickened peritonea (P < 0.01), and the collagen deposition in the parietal peritoneum was increased; also, PIIINP level in plasma was elevated (P < 0.01). Treatment of the PD rats with emodin increased mesothelial cells in peritoneal tissue, and decreased the peritoneal thickness (P < 0.01), collagen depositions, as well as the plasma PIIINP level (P < 0.05). The expressions of Notch1, Jagged-1, Hes-1 and NICD in peritoneal tissue were also attenuated (P < 0.05 or P < 0.01). In cultured rat peritoneal mesothelial cells, compared with emodin group, emodin further inhibited the expressions of Hes-1 and Hey induced by Notch1-overexpression (P < 0.05), but not the expressions of Hes-1 and Hey induced by Notch1-knockdown (P > 0.05). Therefore, the activation of Notch pathway may be involved in the pathological process of PD-induced peritoneal fibrosis. Emodin may ameliorate the PD-related peritoneal fibrosis through inhibiting the activation of Notch pathway.
Subject(s)
Animals , Rats , Blotting, Western , Cells, Cultured , Emodin , Enzyme-Linked Immunosorbent Assay , Epithelial Cells , Epithelium , Peptide Fragments , Peritoneal Dialysis , Peritoneal Fibrosis , Peritoneum , Procollagen , Real-Time Polymerase Chain Reaction , Signal TransductionABSTRACT
To investigate the role of glucose transporter 1 (GLUT1) and sodium-glucose cotransporter 1 (SGLT1) in high glucose dialysate-induced peritoneal fibrosis.Thirty six male SD rats were randomly divided into 6 groups (6 in each):normal control group, sham operation group, peritoneal dialysis group (PD group), PD+phloretin group (PD+T group), PD+phlorizin group (PD+Z group), PD+phloretin+phlorizin group (PD+T+Z group). Rat model of uraemia was established using 5/6 nephrotomy, and 2.5% dextrose peritoneal dialysis solution was used in peritoneal dialysis. Peritoneal equilibration test was performed 24 h after dialysis to evaluate transport function of peritoneum in rats; HE staining was used to observe the morphology of peritoneal tissue; and immunohistochemistry was used to detect the expression of GLUT1, SGLT1, TGF-β1 and connective tissue growth factor (CTGF) in peritoneum. Human peritoneal microvascular endothelial cells (HPECs) were divided into 5 groups:normal control group, peritoneal dialysis group (PD group), PD+phloretin group (PD+T group), PD+phlorezin group (PD+Z group), and PD+phloretin+phlorezin group (PD+T+Z group). Real time PCR and Western blotting were used to detect mRNA and protein expressions of GLUT1, SGLT1, TGF-β1, CTGF in peritoneal membrane and HPECs., compared with sham operation group, rats in PD group had thickened peritoneum, higher ultrafiltration volume, and the mRNA and protein expressions of GLUT1, SGLT1, CTGF, TGF-β1 were significantly increased (all<0.05); compared with PD group, thickened peritoneum was attenuated, and the mRNA and protein expressions of GLUT1, SGLT1, CTGF, TGF-β1 were significantly decreased in PD+T, PD+Z and PD+T+Z groups (all<0.05). Pearson's correlation analysis showed that the expressions of GLUT1, SGLT1 in peritoneum were positively correlated with the expressions of TGF-β1 and CTGF (all<0.05)., the mRNA and protein expressions of GLUT1, SGLT1, TGF-β1, CTGF were significantly increased in HPECs of peritoneal dialysis group (all<0.05), and those in PD+T, PD+Z, and PD+T+Z groups were decreased (all<0.05). Pearson's correlation analysis showed that the expressions of GLUT1, SGLT1 in HPECs were positively correlated with the expressions of TGF-β1 and CTGF (all<0.05).High glucose peritoneal dialysis fluid may promote peritoneal fibrosis by upregulating the expressions of GLUT1 and SGLT1.
Subject(s)
Animals , Humans , Male , Rats , Cells, Cultured , Connective Tissue Growth Factor , Dialysis Solutions , Chemistry , Pharmacology , Gene Expression Regulation , Glucose , Pharmacology , Glucose Transporter Type 1 , Physiology , Hemodiafiltration , Methods , Peritoneal Dialysis , Methods , Peritoneal Fibrosis , Genetics , Peritoneum , Chemistry , Pathology , Phloretin , Phlorhizin , RNA, Messenger , Rats, Sprague-Dawley , Sodium-Glucose Transporter 1 , Physiology , Transforming Growth Factor beta1 , UremiaABSTRACT
Peritoneal fibrosis is one of the major complications occurring in long-term peritoneal dialysis patients as a result of injury. Peritoneal fibrosis is characterized by submesothelial thickening and fibrosis which is associated with a decline in peritoneal membrane function. The myofibroblast has been identified as the key player involved in the development and progression of peritoneal fibrosis. Activation of the myofibroblast is correlated with expansion of the extracellular matrix and changes in peritoneal membrane integrity. Over the years, epithelial to mesenchymal transition (EMT) has been accepted as the predominant source of the myofibroblast. Peritoneal mesothelial cells have been described to undergo EMT in response to injury. Several animal and in vitro studies support the role of EMT in peritoneal fibrosis; however, emerging evidence from genetic fate-mapping studies has demonstrated that myofibroblasts may be arising from resident fibroblasts and pericytes/perivascular fibroblasts. In this review, we will discuss hypotheses currently surrounding the origin of the myofibroblast and highlight the experimental systems predominantly being used to investigate this.
Subject(s)
Animals , Humans , Extracellular Matrix , Fibroblasts , Fibrosis , In Vitro Techniques , Membranes , Myofibroblasts , Peritoneal Dialysis , Peritoneal FibrosisABSTRACT
Sclerosing encapsulating peritonitis (SEP) is a rare cause of intestinal obstruction that is characterized by a thick fibrotic membrane encasing the small intestine like a cocoon. Accurate preoperative diagnosis is often difficult. We present 2 cases of SEP that were diagnosed preoperatively by contrast-enhanced computed tomography scan. A 38-year-old man and a 56-year-old woman were admitted to Daegu Catholic University Medical Center because of recurrent intestinal obstruction. We performed exploratory laparotomy with doubt of the preoperative diagnosis of SEP. We confirmed the diagnosis of SEP on laparotomy and performed adhesiolysis. Both patients recovered successfully and had no signs of recurrence. A better awareness of SEP and its radiological features should lead to more correct preoperative diagnosis and result in more appropriate management, including surgery.
Subject(s)
Adult , Female , Humans , Middle Aged , Academic Medical Centers , Diagnosis , Intestinal Obstruction , Intestine, Small , Laparotomy , Membranes , Peritoneal Fibrosis , Peritonitis , RecurrenceABSTRACT
A diálise peritoneal constitui uma importante opção terapêutica para o paciente com doença renal crônica (DRC) em estágio 5. Entretanto, a médio-longo prazo, alterações morfofuncionais relacionadas a vários fatores, como bioincompatibilidade das soluções de diálise e infecções peritoneais, entre outros, estabelecem um processo inflamatório e fibrótico na membrana peritoneal, levando à perda da eficiência deste método dialítico. O estado urêmico destes pacientes é um agravante, pois intensifica o processo inflamatório da membrana peritoneal. Estratégias terapêuticas que desacelerem o processo de fibrose da membrana peritoneal dos pacientes com DRC em diálise são de extrema importância. Neste contexto, o presente estudo teve como objetivo estabelecer um modelo de peritonite fibrosante associado à DRC com uremia, que mimetiza a situação clínica, e analisar, neste modelo, o efeito de duas moléculas antifibróticas, o tamoxifeno (TAM) e a BMP-7 (bonemorphogenic protein-7). A DRC com uremia foi induzida em ratos Wistar através da administração de dieta rica em adenina, por um período de 30 dias. Nos últimos 15 dias, com o estado de uremia já estabelecido, os animais receberam injeções intraperitoneais de gluconato de clorexidina para a indução da fibrose peritoneal (FP). Os tratamentos com tamoxifeno (10mg/Kg/dia, por gavagem) e BMP-7 (30ug/Kg, injeções intraperitoneais a cada 3 dias) foram iniciados junto com a indução da fibrose peritoneal. Foram formados 6 grupos experimentais: CONTROLE, animais normais; DRC, animais com doença renal crônica; FP, animais com fibrose peritoneal; DRC/FP, animais com DRC e FP mimetizando a situação clínica; DRC/FP+TAM, animais com DRC e FP tratados com tamoxifeno; e DRC/FP+BMP7, animais com DRC e FP tratados com BMP-7. Durante os 30 dias de seguimento do estudo foram verificados o peso, a pressão arterial, ureia e creatinina séricas dos animais. Ao término deste período os animais foram sacrificados e o peritônio foi...
Peritoneal dialysis is an important therapeutic option for patients with stage 5 chronic kidney disease (CKD). However, at medium and long term, morphological and functional changes related to various factors such as bioincompatibility of dialysis solutions and peritoneal infections, among others, establish an inflammatory and fibrotic process in the peritoneal membrane, leading to a loss of dialysis efficiency. The uremic state of these patients aggravates this situation because it intensifies inflammation of the peritoneal membrane. Therapeutic strategies that slow the process of fibrosis of the peritoneal membrane of patients with CKD on dialysis are extremely important. In this context, the present study aimed to establish a model of peritoneal fibrosis associated with CKD with uremia, that mimics the clinical situation, and analyze the effect of two antifibrotic molecules, tamoxifen (TAM) and the BMP7 (bone morphogenic protein-7), in the proposed model. CKD with uremia was induced in male Wistar rats by adenine in the diet during a period of 30 days. After 15 days, with the state of uremia already established, animals received intraperitoneal injections of chlorhexidine gluconate, for the induction of peritoneal fibrosis (PF). Treatment with TAM (10mg/Kg/day by gavage) and BMP7 (30ug/Kg, intraperitoneal injections every 3 days) were initiated along with the induction of peritoneal fibrosis. Six groups were induced: CONTROL, normal animals; CKD, animals with chronic kidney disease; PF, animals with peritoneal fibrosis; CKD / PF, animals with CKD and PF mimicking the clinical situation; CKD / PF + TAM, animals with CKD and PF treated with tamoxifen; and CKD / PF + BMP7, animals with CKD and PF treated with BMP7. During 30 days of the follow-up study, weight, blood pressure, serum urea and creatinine of the animals were verified. At the end of this period, the animals were sacrificed and the peritoneum was removed and subjected to the following analysis: a)...
Subject(s)
Animals , Male , Rats , Peritoneal Fibrosis , Rats, Wistar , Renal Insufficiency, Chronic , Tamoxifen , UremiaABSTRACT
Cryptococcus neoformans is a fungus that causes opportunistic infections in immunocompromised hosts. Skin lesions are found in 10-20% of systemic cryptococcal infections, usually secondary to cryptococcemia, while primary cutaneous cryptococcosis with cryptococcemia is very rare. We report a case of rapidly spreading cryptococcal cellulitis in a 64-year-old male on maintenance hemodialysis taking steroids for encapsulated peritoneal sclerosis. Bluish bullous cellulitis developed on the left forearm and spread rapidly to the other forearm. We identified C. neoformans in the blood and skin lesions. We treated him successfully with liposomal amphotericin B and fluconazole for 15 months. We also review the literature.